E. Allen Sickmier

E. Allen Sickmier

Auto-generated profile, based on publicly available information

E. Allen Sickmier

Department of Biochemistry and Molecular Biology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland 21205, USA

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2006 in Molecular Cell
Verified
Journal Article
Closed access
ESE. Allen Sickmier
E. Allen Sickmier
KFKatherine E. Frato
Katherine E. Frato
HSHaihong Shen
Haihong Shen
SPShanthi R. Paranawithana
Shanthi R. Paranawithana
MGMichael R. Green
Michael R. Green
CKClara L. Kielkopf
Clara L. Kielkopf

27 November 2012 in PLOS ONE
Verified
Journal Article
Open access
PDF file
RHRandy Hecht
Randy Hecht
YLYue-Sheng Li
Yue-Sheng Li
JSJeonghoon Sun
Jeonghoon Sun
EBEd Belouski
Ed Belouski
MHMichael Hall
Michael Hall
JXJing Xu
Jing Xu
Fibroblast growth factor 21 (FGF21) is a promising drug candidate for the treatment of type 2 diabetes. However, the use of wild type native FGF21 is challenging due to several limitations. Among these are its short half-life, its susceptibility to in vivo proteolytic degradation and its propensity to in vitro aggregation. We here describe a rationale-based protein engineering approach to generate a potent long-acting FGF21 analog with improved resistance to proteolysis and aggregation. A recombinant Fc-FGF21 fusion protein was constructed by fusing the Fc domain of human IgG1 to the N-terminus of human mature FGF21 via a linker peptide. The Fc positioned at the N-terminus was determined to be superior to the C-terminus as the N-terminal Fc fusion retained the βKlotho binding affinity and the in vitro and in vivo potency similar to native FGF21. Two specific point mutations were introduced into FGF21. The leucine to arginine substitution at position 98 (L98R) suppressed FGF21 aggregation at high concentrations and elevated temperatures. The proline to glycine replacement at position 171 (P171G) eliminated a site-specific proteolytic cleavage of FGF21 identified in mice and cynomolgus monkeys. The derived Fc-FGF21(RG) molecule demonstrated a significantly improved circulating half-life while maintaining the in vitro activity similar to that of wild type protein. The half-life of Fc-FGF21(RG) was 11 h in mice and 30 h in monkeys as compared to 1-2 h for native FGF21 or Fc-FGF21 wild type. A single administration of Fc-FGF21(RG) in diabetic mice resulted in a sustained reduction in blood glucose levels and body weight gains up to 5-7 days, whereas the efficacy of FGF21 or Fc-FGF21 lasted only for 1 day. In summary, we engineered a potent and efficacious long-acting FGF21 analog with a favorable pharmaceutical property for potential clinical development.

29 July 2011 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
YCYuan Cheng
Yuan Cheng
TJTed C. Judd
Ted C. Judd
MBMichael D. Bartberger
Michael D. Bartberger
JBJames Brown
James Brown
KCKui Chen
Kui Chen
SWStephen Wood
Stephen Wood

1 January 2005 in Structure
Verified
Journal Article
Closed access
ESE. Allen Sickmier
E. Allen Sickmier
DBDimitris Brekasis
Dimitris Brekasis
SPShanthi Paranawithana
Shanthi Paranawithana
JBJeffrey B. Bonanno
Jeffrey B. Bonanno
MPMark S.B. Paget
Mark S.B. Paget
CKClara L. Kielkopf
Clara L. Kielkopf

22 September 2016 in PLOS ONE
Verified
Journal Article
Open access
PDF file
ESE Allen Sickmier
E Allen Sickmier
RKRobert J M Kurzeja
Robert J M Kurzeja
KMKlaus Michelsen
Klaus Michelsen
MVMukta Vazir
Mukta Vazir
EYEvelyn Yang
Evelyn Yang
ATAndrew S Tasker
Andrew S Tasker
Panitumumab and cetuximab target the epidermal growth factor receptor for the treatment of metastatic colorectal cancer. These therapies provide a significant survival benefit to patients with metastatic colorectal cancer with wild-type RAS. A single point mutation in the ectodomain of EGFR (S468R) confers acquired or secondary resistance in cetuximab treated patients, which is not observed in panitumumab-treated patients. Structural and biophysical studies presented here show this mutation directly blocks cetuximab binding to EGFR domain III and describes a unique mechanism by which panitumumab uses a central cavity to accommodate this mutation.

6 April 2016 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
JJJohn B. Jordan
John B. Jordan
DWDouglas A. Whittington
Douglas A. Whittington
MBMichael D. Bartberger
Michael D. Bartberger
ESE. Allen Sickmier
E. Allen Sickmier
KCKui Chen
Kui Chen
TJTed Judd
Ted Judd